Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 7/20 | 0.46 |
| ▸ | MC4R | P32245 | 6/20 | 0.38 |
| ▸ | MC3R | P41968 | 2/20 | 0.36 |
| ▸ | MC5R | P33032 | 1/20 | 0.35 |
| ▸ | MC1R | Q01726 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | BDKRB1 | P46663 | 2/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4698319 | 0.77 | MC4R (0.41) | MC4RMC3RMC5RMC1R | |
| SCHEMBL4530098 | 0.77 | MC4R (0.43) | MC4RMC3RMC5RMC1R | |
| SCHEMBL4514425 | 0.77 | MC4R (0.43) | MC4RMC3RMC5RMC1R | |
| SCHEMBL4698284 | 0.77 | MC4R (0.40) | MC4RMC3RMC5RMC1R | |
| SCHEMBL4680189 | 0.73 | MC4R (0.37) | MC4RMC3RMC5RMC1ROPRM1 | |
| SCHEMBL4698287 | 0.67 | TACR1 (0.63) | TACR1MC4R | |
| SCHEMBL4703222 | 0.66 | TACR1 (0.57) | TACR1MC4ROPRD1 | |
| SCHEMBL6318956 | 0.64 | TACR1 (0.54) | TACR1MC4RMC3RMC5RMC1R | |
| SCHEMBL4702635 | 0.64 | TACR1 (0.46) | TACR1OPRM1 | |
| SCHEMBL6318950 | 0.64 | TACR1 (0.54) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1416933-B1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEM INC (US) | 2008-01-02 | — | — | EP | claimed |
| US-6977264-B2 | Substituted piperidines and methods of use | AMGEN INC. (US) | 2005-12-20 | — | — | US | claimed |
| US-20040006067-A1 | Substituted piperidines and methods of use | AMGEN INC. | 2004-01-08 | — | — | US | claimed |
| EP-1416933-B1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEM INC (US) | 2008-01-02 | — | — | EP | disclosed |
| US-6977264-B2 | Substituted piperidines and methods of use | AMGEN INC. (US) | 2005-12-20 | — | — | US | disclosed |
| US-20040006067-A1 | Substituted piperidines and methods of use | AMGEN INC. | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006067-A1 | Substituted piperidines and methods of use | MC4R, MC5R, MC1R | TACR1 48/4885MC4R 1/4885MC3R 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.